Ceftazidime-Avibactam plus Aztreonam for the Treatment of Infections by VIM-Type-Producing Gram-Negative Bacteria
This is a retrospective single-center study of 24 patients who received ceftazidime-avibactam plus aztreonam (CZA/ATM) for the treatment of VIM-type-producing Gram-negative bacillus (GNB) infections. The bacteria isolated were in 22 patients and Pseudomonas aeruginosa in 2. Sixteen out of 19 isolate...
Gespeichert in:
| Veröffentlicht in: | Antimicrobial agents and chemotherapy 2022-10, Vol.66 (10), p.e0075122-e0075122 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | e0075122 |
|---|---|
| container_issue | 10 |
| container_start_page | e0075122 |
| container_title | Antimicrobial agents and chemotherapy |
| container_volume | 66 |
| creator | Sempere, Abiu Viñado, Belén Los-Arcos, Ibai Campany, David Larrosa, Nieves Fernández-Hidalgo, Nuria Rodríguez-Pardo, Dolors González-López, Juan José Nuvials, Xavier Almirante, Benito Escolà-Vergé, Laura |
| description | This is a retrospective single-center study of 24 patients who received ceftazidime-avibactam plus aztreonam (CZA/ATM) for the treatment of VIM-type-producing Gram-negative bacillus (GNB) infections. The bacteria isolated were
in 22 patients and Pseudomonas aeruginosa in 2. Sixteen out of 19 isolates showed synergistic activity. Two patients presented clinical failure at day 14, and the 30-day mortality was 17% (4/24). CZA/ATM could be considered an alternative therapy for VIM-type-producing GNB infections. |
| doi_str_mv | 10.1128/aac.00751-22 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_9578418</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2714392155</sourcerecordid><originalsourceid>FETCH-LOGICAL-a418t-e1f6decacf4aac653e27085ff48cdc1e79a88cf174e693dc018accbc7dd5f79a3</originalsourceid><addsrcrecordid>eNp1kc1vEzEQxS0EoqFw44x8BAkX27ve9V6Q0oiWSOXjELhaE-84dZVdp7Y3UvrX15BSwYHTaDRPv5k3j5DXgp8JIfUHAHvGeasEk_IJmQneadaornlKZpw3Das1r0_Ii5RueOlVx5-Tk6oRXDaVmpHbBboMd773A7L53q_BZhjobjslOr_LEcNYWhcizddIVxEhDzhmGhxdjg5t9mFMdH2gP5df2OqwQ_Y9hn6yftzQywgD-4obyH6P9LyQMXp4SZ452CZ89VBPyY-LT6vFZ3b17XK5mF8xqIXODIVrerRgXV0cNqpC2XKtnKu17a3AtgOtrRNtjU1X9ZYLDdaubdv3ypVhdUo-Hrm7aT1gb8vVEbZmF_0A8WACePPvZPTXZhP2plOtLicUwNsHQAy3E6ZsBp8sbrcwYpiSka2oq04KpYr0_VFqY0gpontcI7j5lZIpHszvlIyURf7uKIc0SHMTpjiWT_xP--ZvG4_gPxFW93fGnho</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2714392155</pqid></control><display><type>article</type><title>Ceftazidime-Avibactam plus Aztreonam for the Treatment of Infections by VIM-Type-Producing Gram-Negative Bacteria</title><source>MEDLINE</source><source>EZB-FREE-00999 freely available EZB journals</source><source>PubMed Central</source><creator>Sempere, Abiu ; Viñado, Belén ; Los-Arcos, Ibai ; Campany, David ; Larrosa, Nieves ; Fernández-Hidalgo, Nuria ; Rodríguez-Pardo, Dolors ; González-López, Juan José ; Nuvials, Xavier ; Almirante, Benito ; Escolà-Vergé, Laura</creator><creatorcontrib>Sempere, Abiu ; Viñado, Belén ; Los-Arcos, Ibai ; Campany, David ; Larrosa, Nieves ; Fernández-Hidalgo, Nuria ; Rodríguez-Pardo, Dolors ; González-López, Juan José ; Nuvials, Xavier ; Almirante, Benito ; Escolà-Vergé, Laura</creatorcontrib><description>This is a retrospective single-center study of 24 patients who received ceftazidime-avibactam plus aztreonam (CZA/ATM) for the treatment of VIM-type-producing Gram-negative bacillus (GNB) infections. The bacteria isolated were
in 22 patients and Pseudomonas aeruginosa in 2. Sixteen out of 19 isolates showed synergistic activity. Two patients presented clinical failure at day 14, and the 30-day mortality was 17% (4/24). CZA/ATM could be considered an alternative therapy for VIM-type-producing GNB infections.</description><identifier>ISSN: 0066-4804</identifier><identifier>EISSN: 1098-6596</identifier><identifier>DOI: 10.1128/aac.00751-22</identifier><identifier>PMID: 36102635</identifier><language>eng</language><publisher>United States: American Society for Microbiology</publisher><subject>Anti-Bacterial Agents - therapeutic use ; Antimicrobial Chemotherapy ; Azabicyclo Compounds - therapeutic use ; Aztreonam - therapeutic use ; beta-Lactamases ; Ceftazidime - therapeutic use ; Clinical Therapeutics ; Drug Combinations ; Gram-Negative Bacteria ; Humans ; Microbial Sensitivity Tests ; Retrospective Studies</subject><ispartof>Antimicrobial agents and chemotherapy, 2022-10, Vol.66 (10), p.e0075122-e0075122</ispartof><rights>Copyright © 2022 American Society for Microbiology.</rights><rights>Copyright © 2022 American Society for Microbiology. 2022 American Society for Microbiology</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-a418t-e1f6decacf4aac653e27085ff48cdc1e79a88cf174e693dc018accbc7dd5f79a3</citedby><cites>FETCH-LOGICAL-a418t-e1f6decacf4aac653e27085ff48cdc1e79a88cf174e693dc018accbc7dd5f79a3</cites><orcidid>0000-0001-8835-2702 ; 0000-0003-2419-5909 ; 0000-0002-5608-3090 ; 0000-0002-2115-344X</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC9578418/pdf/$$EPDF$$P50$$Gpubmedcentral$$H</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC9578418/$$EHTML$$P50$$Gpubmedcentral$$H</linktohtml><link.rule.ids>230,314,727,780,784,885,27924,27925,53791,53793</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/36102635$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Sempere, Abiu</creatorcontrib><creatorcontrib>Viñado, Belén</creatorcontrib><creatorcontrib>Los-Arcos, Ibai</creatorcontrib><creatorcontrib>Campany, David</creatorcontrib><creatorcontrib>Larrosa, Nieves</creatorcontrib><creatorcontrib>Fernández-Hidalgo, Nuria</creatorcontrib><creatorcontrib>Rodríguez-Pardo, Dolors</creatorcontrib><creatorcontrib>González-López, Juan José</creatorcontrib><creatorcontrib>Nuvials, Xavier</creatorcontrib><creatorcontrib>Almirante, Benito</creatorcontrib><creatorcontrib>Escolà-Vergé, Laura</creatorcontrib><title>Ceftazidime-Avibactam plus Aztreonam for the Treatment of Infections by VIM-Type-Producing Gram-Negative Bacteria</title><title>Antimicrobial agents and chemotherapy</title><addtitle>Antimicrob Agents Chemother</addtitle><addtitle>Antimicrob Agents Chemother</addtitle><description>This is a retrospective single-center study of 24 patients who received ceftazidime-avibactam plus aztreonam (CZA/ATM) for the treatment of VIM-type-producing Gram-negative bacillus (GNB) infections. The bacteria isolated were
in 22 patients and Pseudomonas aeruginosa in 2. Sixteen out of 19 isolates showed synergistic activity. Two patients presented clinical failure at day 14, and the 30-day mortality was 17% (4/24). CZA/ATM could be considered an alternative therapy for VIM-type-producing GNB infections.</description><subject>Anti-Bacterial Agents - therapeutic use</subject><subject>Antimicrobial Chemotherapy</subject><subject>Azabicyclo Compounds - therapeutic use</subject><subject>Aztreonam - therapeutic use</subject><subject>beta-Lactamases</subject><subject>Ceftazidime - therapeutic use</subject><subject>Clinical Therapeutics</subject><subject>Drug Combinations</subject><subject>Gram-Negative Bacteria</subject><subject>Humans</subject><subject>Microbial Sensitivity Tests</subject><subject>Retrospective Studies</subject><issn>0066-4804</issn><issn>1098-6596</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp1kc1vEzEQxS0EoqFw44x8BAkX27ve9V6Q0oiWSOXjELhaE-84dZVdp7Y3UvrX15BSwYHTaDRPv5k3j5DXgp8JIfUHAHvGeasEk_IJmQneadaornlKZpw3Das1r0_Ii5RueOlVx5-Tk6oRXDaVmpHbBboMd773A7L53q_BZhjobjslOr_LEcNYWhcizddIVxEhDzhmGhxdjg5t9mFMdH2gP5df2OqwQ_Y9hn6yftzQywgD-4obyH6P9LyQMXp4SZ452CZ89VBPyY-LT6vFZ3b17XK5mF8xqIXODIVrerRgXV0cNqpC2XKtnKu17a3AtgOtrRNtjU1X9ZYLDdaubdv3ypVhdUo-Hrm7aT1gb8vVEbZmF_0A8WACePPvZPTXZhP2plOtLicUwNsHQAy3E6ZsBp8sbrcwYpiSka2oq04KpYr0_VFqY0gpontcI7j5lZIpHszvlIyURf7uKIc0SHMTpjiWT_xP--ZvG4_gPxFW93fGnho</recordid><startdate>20221018</startdate><enddate>20221018</enddate><creator>Sempere, Abiu</creator><creator>Viñado, Belén</creator><creator>Los-Arcos, Ibai</creator><creator>Campany, David</creator><creator>Larrosa, Nieves</creator><creator>Fernández-Hidalgo, Nuria</creator><creator>Rodríguez-Pardo, Dolors</creator><creator>González-López, Juan José</creator><creator>Nuvials, Xavier</creator><creator>Almirante, Benito</creator><creator>Escolà-Vergé, Laura</creator><general>American Society for Microbiology</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0001-8835-2702</orcidid><orcidid>https://orcid.org/0000-0003-2419-5909</orcidid><orcidid>https://orcid.org/0000-0002-5608-3090</orcidid><orcidid>https://orcid.org/0000-0002-2115-344X</orcidid></search><sort><creationdate>20221018</creationdate><title>Ceftazidime-Avibactam plus Aztreonam for the Treatment of Infections by VIM-Type-Producing Gram-Negative Bacteria</title><author>Sempere, Abiu ; Viñado, Belén ; Los-Arcos, Ibai ; Campany, David ; Larrosa, Nieves ; Fernández-Hidalgo, Nuria ; Rodríguez-Pardo, Dolors ; González-López, Juan José ; Nuvials, Xavier ; Almirante, Benito ; Escolà-Vergé, Laura</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-a418t-e1f6decacf4aac653e27085ff48cdc1e79a88cf174e693dc018accbc7dd5f79a3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>Anti-Bacterial Agents - therapeutic use</topic><topic>Antimicrobial Chemotherapy</topic><topic>Azabicyclo Compounds - therapeutic use</topic><topic>Aztreonam - therapeutic use</topic><topic>beta-Lactamases</topic><topic>Ceftazidime - therapeutic use</topic><topic>Clinical Therapeutics</topic><topic>Drug Combinations</topic><topic>Gram-Negative Bacteria</topic><topic>Humans</topic><topic>Microbial Sensitivity Tests</topic><topic>Retrospective Studies</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Sempere, Abiu</creatorcontrib><creatorcontrib>Viñado, Belén</creatorcontrib><creatorcontrib>Los-Arcos, Ibai</creatorcontrib><creatorcontrib>Campany, David</creatorcontrib><creatorcontrib>Larrosa, Nieves</creatorcontrib><creatorcontrib>Fernández-Hidalgo, Nuria</creatorcontrib><creatorcontrib>Rodríguez-Pardo, Dolors</creatorcontrib><creatorcontrib>González-López, Juan José</creatorcontrib><creatorcontrib>Nuvials, Xavier</creatorcontrib><creatorcontrib>Almirante, Benito</creatorcontrib><creatorcontrib>Escolà-Vergé, Laura</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Antimicrobial agents and chemotherapy</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Sempere, Abiu</au><au>Viñado, Belén</au><au>Los-Arcos, Ibai</au><au>Campany, David</au><au>Larrosa, Nieves</au><au>Fernández-Hidalgo, Nuria</au><au>Rodríguez-Pardo, Dolors</au><au>González-López, Juan José</au><au>Nuvials, Xavier</au><au>Almirante, Benito</au><au>Escolà-Vergé, Laura</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Ceftazidime-Avibactam plus Aztreonam for the Treatment of Infections by VIM-Type-Producing Gram-Negative Bacteria</atitle><jtitle>Antimicrobial agents and chemotherapy</jtitle><stitle>Antimicrob Agents Chemother</stitle><addtitle>Antimicrob Agents Chemother</addtitle><date>2022-10-18</date><risdate>2022</risdate><volume>66</volume><issue>10</issue><spage>e0075122</spage><epage>e0075122</epage><pages>e0075122-e0075122</pages><issn>0066-4804</issn><eissn>1098-6596</eissn><abstract>This is a retrospective single-center study of 24 patients who received ceftazidime-avibactam plus aztreonam (CZA/ATM) for the treatment of VIM-type-producing Gram-negative bacillus (GNB) infections. The bacteria isolated were
in 22 patients and Pseudomonas aeruginosa in 2. Sixteen out of 19 isolates showed synergistic activity. Two patients presented clinical failure at day 14, and the 30-day mortality was 17% (4/24). CZA/ATM could be considered an alternative therapy for VIM-type-producing GNB infections.</abstract><cop>United States</cop><pub>American Society for Microbiology</pub><pmid>36102635</pmid><doi>10.1128/aac.00751-22</doi><tpages>6</tpages><orcidid>https://orcid.org/0000-0001-8835-2702</orcidid><orcidid>https://orcid.org/0000-0003-2419-5909</orcidid><orcidid>https://orcid.org/0000-0002-5608-3090</orcidid><orcidid>https://orcid.org/0000-0002-2115-344X</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0066-4804 |
| ispartof | Antimicrobial agents and chemotherapy, 2022-10, Vol.66 (10), p.e0075122-e0075122 |
| issn | 0066-4804 1098-6596 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_9578418 |
| source | MEDLINE; EZB-FREE-00999 freely available EZB journals; PubMed Central |
| subjects | Anti-Bacterial Agents - therapeutic use Antimicrobial Chemotherapy Azabicyclo Compounds - therapeutic use Aztreonam - therapeutic use beta-Lactamases Ceftazidime - therapeutic use Clinical Therapeutics Drug Combinations Gram-Negative Bacteria Humans Microbial Sensitivity Tests Retrospective Studies |
| title | Ceftazidime-Avibactam plus Aztreonam for the Treatment of Infections by VIM-Type-Producing Gram-Negative Bacteria |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-07T18%3A05%3A19IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Ceftazidime-Avibactam%20plus%20Aztreonam%20for%20the%20Treatment%20of%20Infections%20by%20VIM-Type-Producing%20Gram-Negative%20Bacteria&rft.jtitle=Antimicrobial%20agents%20and%20chemotherapy&rft.au=Sempere,%20Abiu&rft.date=2022-10-18&rft.volume=66&rft.issue=10&rft.spage=e0075122&rft.epage=e0075122&rft.pages=e0075122-e0075122&rft.issn=0066-4804&rft.eissn=1098-6596&rft_id=info:doi/10.1128/aac.00751-22&rft_dat=%3Cproquest_pubme%3E2714392155%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2714392155&rft_id=info:pmid/36102635&rfr_iscdi=true |